Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells 52,847 Shares of Stock

Key Points

• Merck EVP David Michael Williams sold 52,847 shares at an average price of $128.77, generating approximately $6.81 million. His remaining direct ownership fell 62.49% to 31,716 shares.
• Merck reported quarterly revenue of $16.61 billion, exceeding estimates of $16.37 billion, while adjusted EPS of $(0.13) beat the consensus estimate of $(0.26); revenue increased 5.1% year over year.
• The company declared a quarterly dividend of $0.85, equivalent to $3.40 annually and a 2.6% yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $134.56, compared with a recent share price of $128.61.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) EVP David Michael Williams sold 52,847 shares of the company's stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares in the company, valued at $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Merck & Co., Inc. Stock Up 0.2%

MRK traded up $0.24 during trading on Friday, reaching $128.61. 6,425,060 shares of the stock traded hands, compared to its average volume of 10,766,726. The stock has a market cap of $317.64 billion, a price-to-earnings ratio of 102.89, a price-to-earnings-growth ratio of 5.14 and a beta of 0.19. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.05. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock's 50-day simple moving average is $123.78 and its two-hundred day simple moving average is $119.04.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the prior year, the firm posted $2.13 EPS. The business's revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 2.72 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.'s payout ratio is 272.00%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of MRK. Kingdom Financial Group LLC. bought a new stake in Merck & Co., Inc. during the 4th quarter valued at approximately $25,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. Prosperity Bancshares Inc bought a new position in Merck & Co., Inc. in the 4th quarter worth approximately $26,000. High Note Wealth LLC lifted its holdings in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after buying an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $31,000. Institutional investors own 76.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Weiss Ratings lowered shares of Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a research note on Friday, May 15th. JPMorgan Chase & Co. increased their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. BMO Capital Markets raised their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an "outperform" rating in a report on Monday, July 13th. UBS Group boosted their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Monday, April 13th. Finally, Guggenheim upped their price target on Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a "buy" rating in a research note on Wednesday. Thirteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $134.56.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source